UMIT Private University for Health Sciences Medical Informatics and Technology: Results of a Collaborative Study at Campus Tyrol Argue in Favor of a Personalized Prostate Cancer Screening Approach

Food and Healthcare Press Releases Tuesday July 4, 2017 09:00
HALL, Austria--4 Jul--PRNewswire/InfoQuest

A simulation study published in BMC Public Health by researchers of the Tyrolean Health and Life Sciences University UMIT, the Oncotyrol center, the Medical University of Innsbruck and the University of Toronto highlights optimized use of prostate cancer screening.

(Photo: http://mma.prnewswire.com/media/529873/UMIT_Dr_Uwe_Siebert.jpg )
(Photo: http://mma.prnewswire.com/media/529874/UMIT_Nikolai_Muhlberger.jpg )

"Like most medical procedures also screening harbors benefits and risks. This gains increasing attention by the public," explains Prof. Dr. Uwe Siebert, Chair of the Department of Public Health, Health Services Research and Health Technology Assessment at UMIT and President-Elect of the Society for Medical Decision Making. "A major risk of prostate cancer screening is that of overdiagnosis and overtreatment. This refers to the diagnosis and treatment of clinically irrelevant tumors, which would not cause any complaints during men's lifetime and remain undetected without screening. Currently, there is no reliable method to distinguish clinically relevant from clinically irrelevant tumors. In consequence, also clinically irrelevant tumors may be treated, which unnecessarily exposes the affected patients to the unfortunately not uncommon long-term treatment complications such as erectile dysfunction, incontinence, bowel dysfunction."

The simulation model developed by the researchers within a ONCOTYROL research project for personalized medicine simulates the positive and negative effects of screening on the duration and quality of life of screening participants and analyses under which circumstances the potential harms of screening outweigh the potential benefits. Project Coordinator Ass. Prof. Dr. Nikolai Muhlberger summarizes the study findings as follows: "The study results suggest that participation in screening reduces the risk to die from prostate cancer and prolongs the life expectancy of participating men. However, when quality-of-life effects are considered as well, it is shown that primarily men with elevated familial prostate cancer risk benefit from screening, while in men with average prostate cancer risk overall the harms of screening prevail. In addition, the simulation predicts that the benefit of screening in men with elevated familial risk also strongly depends on their individual valuation of treatment-related long-term side-effects."

The urological experts in the research team, Prof. Dr. Wolfgang Horninger und Prof. Dr. Helmut Klocker, see the study as an important contribution towards a targeted application of prostate cancer screening. Horninger, the Dean of the Department of Urology at the Medical University of Innsbruck explains: "The study highlights the problem of overdiagnosis and illustrates the dependency of screening benefits on individual risk factors and preferences. Thus, it contributes to the improvement of patient counseling and supports an individual use of screening examinations, which all of us consider as important issues."

Contact: Prof. Dr. Uwe Siebert,   public-health@umit.at , +4350-8648-673930
Source: UMIT - The Health & Life Sciences University

Latest Press Release

Biotech Conagen Acquires Production Platform of Therapeutic Proteins

Conagen, a vertically integrated synthetic biology company located in Boston's biotech corridor, announced today that it has acquired a fermentation-based technology for the production of therapeutically useful glycoproteins. The acquisition includes...

Pneuma Respiratory, Inc. Announces New Chairman of the Board

Pneuma Respiratory, Inc. announced that Board member Jay Morgan has assumed the position of Chairman of the Board. Pneuma's previous Chairman, Walt Robb, will remain a member of the Board of Directors. Jay Morgan served as VP Global Innovation and...

Global market of dietary supplement is welcoming a rising star GLYMATE

Glymate(TM), a newly founded nutraceutical company in Southern California. Its proprietary sugar balance dietary supplement was officially announced in the United States in June 2019, marking the official launch of the global marketing of this product,...

Xinhua Silk Road: Tasly remains China#s 2019 National Tech Innovation Demonstration Enterprise

Tasly Holding Group, one of China's leading pharmaceuticals companies, has recently passed through the country's review of National Technology Innovation Demonstration Enterprise in 2019, thanks to its continuous innovations made in the recent...

SweeGen#s non-GMO Reb M Stevia Leaf Sweetener Approved in Singapore

SweeGen, Inc., a nature-based sweetener company, announced the Singapore Food Agency has added SweeGen's Reb M Stevia Leaf Sweetener to the list of permitted food additives. SweeGen's Reb M is a non-caloric stevia sweetener that provides sweetness with...

Related Topics